Data were locked for analysis on January 23, 2019. Survival endpoint probabilities were estimated using the Kaplan-Meier
method with 95% confidence intervals (CI). Cumulative incidences (CuI) of transplant-related mortality (TRM), GVHD, count
recovery, and graft failure were estimated by competing-risk analysis using Gray’s method. Death was a competing risk for
all analyses except TRM; relapse of pre-BMT malignancy was a competing risk for TRM. Graft failure was a competing risk for
GVHD.
Data were analyzed with
R, version 3.3.3 (
https://www.R-project.org, R-Foundation for Statistical Computing) and
Prism, version 8.0(GraphPad Software)
Dimitrova D., Gea-Banacloche J., Steinberg S.M., Sadler J.L., Hicks S.N., Carroll E., Wilder J.S., Parta M., Skeffington L., Hughes T.E., Blau J.E., Broadney M.M., Rose J.J., Hsu A.P., Fletcher R., Nunes N.S., Yan X.Y., Telford W.G., Kapoor V., Cohen J.I., Freeman A.F., Garabedian E., Holland S.M., Lisco A., Malech H.L., Notarangelo L.D., Sereti I., Shah N.N., Uzel G., Zerbe C.S., Fowler D.H., Gress R.E., Kanakry C.G, & Kanakry J.A. (2019). Prospective study of a novel, radiation-free, reduced-intensity bone marrow transplantation platform for primary immunodeficiency diseases. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 26(1), 94-106.